Abstract: The invention discloses a ring-fused compound, a preparation method thereof, pharmaceutical composition containing the compound and an application of the compound. A polycyclic compound (I) as well asan isomer, a prodrug, a stable isotopic derivative or pharmacologically acceptable salt of the compound (I) has the following structure. The polycyclic compound has good IDO1 and/or TDO2 inhibition functions, can effectively treat, relieve and/or prevent various diseases which are related with IDO1 and/or TDO2, such as cancer, virus infection, autoimmune diseases or the like.

Abstract: The invention discloses a polycyclic compound as well as a preparation method, a pharmaceutical composition and application thereof. The polycyclic compound (I), isomers, prodrugs, solvent compounds,hydrates, stable isotope derivatives or pharmaceutically-acceptable salts have the following structure. The polycyclic compound has a good IDO1 suppressing effect, and can be used for effectively treating, relieving and/or preventing various relevant diseases such as tumors, virus infection or autoimmune diseases caused by immunosuppression. The structural formula is shown in the description.

Abstract: The present invention relates to a polycyclic compound and an organic electroluminescent device containing the same. According to an embodiment of the present invention, the polycyclic compound is represented by chemical formula 1. More specifically, provided is a polycyclic compound capable of being used in organic electroluminescent devices with high luminous efficiency.

Abstract: The invention discloses a polycyclic compound and its preparation method, pharmaceutical composition and application The polycyclic compound (I) and its isomer, prodrug, solvate, hydrate, stable isotope derivative or pharmaceutically acceptable salt have the structure shown in the description The polycyclic compound has good IDO1 inhibitory effects and can be used for effectively treating, alleviating and/or preventing various related diseases such as tumors, virus infection or autoimmune diseases caused by immunosuppression

Abstract: Provided are a polycyclic compound and a manufacturing method, pharmaceutical composition, and application thereof The structure of the polycyclic compound and an isomer, prodrug, solvate, hydrate, stable isotopic derivative, or pharmaceutically acceptable salt thereof are represented by formula (I) The polycyclic compound has an excellent inhibitory effect against ID01, and can effectively treat, mitigate and/or prevent various diseases caused by immunosuppression, including an autoimmune disease caused by a tumor or viral infection

Abstract: PROBLEM TO BE SOLVED: To provide a novel condensed polycyclic compound of cyclopenta[hi]aceanthrylene structure, and provide a near infrared light absorbing material and an organic electronic device comprising the same.SOLUTION: The present invention provides a compound of general formula (1) (Rand Rindependently represent an aliphatic hydrocarbon group, an alicyclic hydrocarbon group, an aromatic hydrocarbon group or a heterocyclic group; Rand Rindependently represent H or an electron-withdrawing substituent; A is an aromatic hydrocarbon group or a heterocyclic group; n is 0 or 1; preferably the electron attractive groups of Rand Rare halogen, a cyano group, a nitro group, a sulfo group or an acyl group, particularly preferably Rand Rare H).SELECTED DRAWING: None

Abstract: The invention discloses a condensed polycyclic compound. The polycyclic compound has a structure shown as a formula (I) or a formula (II). The condensed polycyclic compound has a high triplet state energy level and glassy state conversion temperature and can ensure efficient transmission of energy to an object material after being adopted as a luminous layer main material; the polycyclic compoundis not likely to be crystalized, and the luminous efficiency of components is improved conveniently. By adjusting a substituent group of the condensed polycyclic compound to achieve the electronic transmission capability and the hole transmission capability, the energy level difference between a singlet state and a triplet state is decreased, a compound area of current carriers is expanded, and annihilation of triplet state excitons is avoided. The invention also discloses an organic electroluminescence device, and at least one function layer of the device contains the condensed polycyclic compound; the condensed polycyclic compound serves as the main material of a luminous layer and is matched with the energy level of an adjacent current carrier transmission layer; the luminous efficiencyof the components is improved, the driving voltage of the components is lowered at the same time, and effective usage of the organic electroluminescence device for a long time is achieved more conveniently.

Abstract: To form a film-form molded article that includes a compound represented by formula (1) and also includes a compound represented by formula (A) after a heating step for heating a coating film formed on a substrate. (In the formulas, rings A1 and A2 have at least one carbon-carbon unsaturated bond; R1a and R1b are hydrogen atoms or substituent groups; RA and RB are hydrogen atoms, substituent groups, or group 16 elements in the periodic table; p1 and p2 are integers of 0 or higher; Z is a group 13-16 element in the periodic table; R2 is a hydrogen atom or a substituent group; R3 is a group 16 element in the periodic table; m is an integer of 0-4; and n is an integer of 0-2. The bond shown by (2) is a single bond or double bond.) This method makes it possible to easily and efficiently produce a film-form molded article that includes a condensed polycyclic compound in which a condensed ring is formed at each of positions 1 and 2 and positions 3 and 4 of a benzene ring.

Abstract: The invention discloses a polycyclic compound and an organic light-emitting device including the same The compound is represented by the formula 1 The organic light-emitting device comprising the polycyclic compound has the advantages of low drive voltage, high efficiency, high brightness, and long service life

Abstract: The invention discloses a nitrogen-containing aromatic polycyclic compound, which is specifically of the following structure: as shown in the specification, wherein marks from R1 to R11 are the same or different, representing -H, -F, -Cl, -Br, -I, hydroxyl, sulfydryl, amino, alkyl from C1 to C8, alkoxy from C1 to C18, alkane thiol from C1 to C18, alkyl amino from C1 to C18, aryloxy, aromatic thiol, aromatic amino or carbazolyl; R12 represents -H, methyl, amine methyl, cyan, guanyl and substituted or non-substituted pyrimidyl; R13 represents -H, cyan, methyl or amine methyl. The phthalein red compound is high in planarity; the aromaticity and the spectrum shape of the compound are similar to the aromaticity and the spectrum shape of phthalocyanine, but the dissolvability is higher; comparedwith the phthalocyanine, the phthalein red compound is easier to process. The nitrogen-containing aromatic polycyclic compound can be used as a p-type semiconductor material used in the field of molecular conductor materials, molecular electron component materials, electrochromic materials, photoelectric conversion materials or OLED materials.

Abstract: The invention discloses polycyclic compound sodium salt, a crystal form of sodium salt as well as a preparation method and an application of the crystal form. The polycyclic compound sodium salt has the crystal form G shown in a formula II, has good stability and absorbability and is easily crushed into powder with a large surface area after being dried, and preparation and use of pharmaceutical composition are easy.

Abstract: The invention discloses a polycyclic compound and its preparation method, pharmaceutical composition and application. The polycyclic compound (I) and its isomer, prodrug, stable isotope derivative ora pharmaceutically acceptable salt have the structure shown in the description. The polycyclic compound has good IDO1 inhibitory effects and can be used for effectively treating, alleviating and/or preventing various related diseases such as tumors and infectious diseases caused by immunosuppression.

Abstract: This condensed polycyclic compound is represented by formula (1). (In the formula: Z, Z1, and Z2 may be the same or different, and each represent atoms selected from group 13, 14, 15, or 16 elements of the periodic table; R1a, R1b, R2, R2a, R2b, R4a, R4b, R5a, and R5b may be the same or different, and individually represent a hydrogen atom or a substituent; R3, R3a, and R3b may be the same or different, and individually represent an atom selected from group 16 elements of the periodic table; m, m1, and m2 may be the same or different, and individually represent an integer from 0 to 4; and n, n1, and n2 may be the same or different, and individually represent an integer from 0 to 2). The condensed polycyclic compound exhibits high solubility in organic solvents even in the absence of a substituent such as a long-chain alkyl group.